Fingolimod (FTY720) HCl

For research use only.

Catalog No.S5002

81 publications

Fingolimod (FTY720) HCl Chemical Structure

CAS No. 162359-56-0

Fingolimod (FTY720) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 91 In stock
USD 97 In stock
USD 170 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Fingolimod (FTY720) HCl has been cited by 81 publications

Purity & Quality Control

Choose Selective S1P Receptor Inhibitors

Biological Activity

Description Fingolimod (FTY720) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.
Targets
S1P receptor [1]
(K562, NK cells )
0.033 nM
In vitro

The inhibitory effect of S1P is revered by various concentrations of FTY720, with IC50 effect of 173 nM. In addition, FTY720 (10 nM) alone exerts no effect on the expression of co-stimulatory molecules. FTY720 reverses the increased expression of HLA-I induced by S1P for both the percentages of cells and the MFI, upon comparing the effect of S1P to the effect of combining S1P with FTY720. [1] Medium and high-dose FTY720-P also enhances the levels of TGF-β1. TGF-β1 and Foxp3 mRNA expression are upregulated in the high-dose FTY720-P group. The proliferation of effector T cells is suppressed significantly in the medium and high-dose FTY720-P group at a Treg/Teff cell ratio of 1:1. At a ratio of 1:1, the proliferation of effector T cells is also suppressed in the high-dose FTY720 group. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human U2OS cells NGrjT41HfW6ldHnvckBie3OjeR?= NFj3XHpC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHMyWDFicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJIh2dWGwIGWyU3Mh[2WubIOgZ48u\XiycnXzd4lv\yCnR1\QJIF{e2W|c3XkJIF{KHKnY3XweI9zKGmwdHXycoFtcXqjdHnvckBqdnSxIHP5eI9xdGG|bTD1d4lv\yCKb3XjbJN1KGS7ZTDzeIFqdmmwZzygSWM2OD1yLkCwNkDPxE1w M1LUblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUC0NVQ1Lz5{MkGwOFE1PDxxYU6=
human PC3 cells MmD3R5l1d3SxeHnjxsBie3OjeR?= M3qwZ|czKGh? NVHhcIhHS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KGGodHXyJFczKGi{czDifUB3cXSjbDDkfYUh\XilbIXzbY9vN2[ub4egZ5l1d22ndILpZ{BidmGueYPpd{whUUN3ME25Mlgh|ryPLh?= MkjRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{N{O2N|IoRjJ2MkezOlMzRC:jPh?=
human NALM6 cells MkjLR5l1d3SxeHnjxsBie3OjeR?= Mmj5O|IhcA>? M2jzWmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KFCqLX7l[4F1cX[nIHj1cYFvKE6DTF22JINmdGy|IHHmeIVzKDd{IHjyd{BjgSC4aYThcEBlgWViZYjjcJV{cW:wL3\sc5ch[3m2b33leJJq[yCjbnHsfZNqeyxiSVO1NF06NjZizszNMi=> NETTWmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK3N|Y{Oid-MkSyO|M3OzJ:L3G+
human CCRF-CEM cells MnK3R5l1d3SxeHnjxsBie3OjeR?= M1zLb|czKGh? NH61WFZEgXSxdH;4bYNqfHliYXfhbY5{fCCSaD3u[YdifGm4ZTDoeY1idiCFQ2LGMWNGVSClZXzsd{Bi\nSncjC3NkBpenNiYomgeol1[WxiZInlJIV5[2y3c3nvck9ndG:5IHP5eI9u\XS{aXOgZY5idHm|aYOsJGlEPTB;Nj64JO69VS5? NEjJT3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK3N|Y{Oid-MkSyO|M3OzJ:L3G+
human SUP-B15 cells MkXLR5l1d3SxeHnjxsBie3OjeR?= MoDmO|IhcA>? M2nLVGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KFCqLYDvd4l1cX[nIHj1cYFvKFOXUD3CNVUh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7II\peIFtKGS7ZTDlfINtfXOrb36v[oxwfyCleYTvcYV1emmlIHHuZYx6e2m|LDDJR|UxRTZwODFOwG0v MnPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{N{O2N|IoRjJ2MkezOlMzRC:jPh?=
human DU145 cells NUHrNJh5S3m2b4TvfIlkyqCjc4PhfS=> M33mflczKGh? MY\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bi\nSncjC3NkBpenNiYomgeol1[WxiZInlJIV5[2y3c3nvck9ndG:5IHP5eI9u\XS{aXOgZY5idHm|aYOsJGlEPTB;Nj61JO69VS5? MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ5M{[zNkc,OjR{N{O2N|I9N2F-
human BV173 cells Ml\YR5l1d3SxeHnjxsBie3OjeR?= MnfjO|IhcA>? NV7HWVZrS3m2b4TvfIlkcXS7IHHnZYlve3RiUHitdI9{cXSrdnWgbJVu[W5iQm[xO|Mh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7II\peIFtKGS7ZTDlfINtfXOrb36v[oxwfyCleYTvcYV1emmlIHHuZYx6e2m|LDDJR|UxRTZwMzFOwG0v NXLJNpFoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyO|M3OzJpPkK0Nlc{PjN{PD;hQi=>
human BLIN-1 cells NGSyXWlEgXSxdH;4bYPDqGG|c3H5 MUO3NkBp MnPCR5l1d3SxeHnjbZR6KGGpYXnud5QhWGhvbnXnZZRqfmViaIXtZY4hSkyLTj2xJINmdGy|IHHmeIVzKDd{IHjyd{BjgSC4aYThcEBlgWViZYjjcJV{cW:wL3\sc5ch[3m2b33leJJq[yCjbnHsfZNqeyxiSVO1NF02NjVizszNMi=> M3PIO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkezOlMzLz5{NEK3N|Y{OjxxYU6=
mouse bone marrow cells MYDDfZRwfG:6aXRCpIF{e2G7 M1XJWFczKGh? M1fTemN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEKFUj3BRmwh\nW|aX;uJJBzd3SnaX6gNVkxKGW6cILld5NqdmdibX;1d4Uh[m:wZTDtZZJzd3diY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJZqfGGuIHT5[UBmgGOudYPpc44w\myxdzDjfZRwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyPUOuN{DPxE1w NFH3epI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK3N|Y{Oid-MkSyO|M3OzJ:L3G+
Sf9 insect cells M4jLWWZ2dmO2aX;uJIF{e2G7 M{TwPFEhcA>? NH\FcXJKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGOxVGwhMDZ{IITvJFU3QCliZYjwdoV{e2WmIHnuJHNnQSCrboPlZ5Qh[2WubIOgeZNqdmdiU{HQJIF{KHO3YoP0doF1\SCjZoTldkAyKGi{ MorEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MEm4NVQoRjJ2OEC5PFE1RC:jPh?=
mouse MN9D cells M2fyWWZ2dmO2aX;uJIF{e2G7 Mly4OUDPxE1? MWHJcoR2[3Srb36gc4YhWFB{QTDjZZRidHm2aXOgd5VjfW6rdDDhZ5Rqfmm2eTDpckBud3W|ZTDNUllFKGOnbHzzJIF{e2W|c3XkJIF{KHCqb4PwbIF1\SCuZY\lcEBifCB3IIXN Mn[5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUCxOlUoRjJ3MEWwNVY2RC:jPh?=
rat PC12 cells MWrGeY5kfGmxbjDhd5NigQ>? MkDkOUDPxE1? MUezNEB1dyBzMkCgcYlvew>? M17BdGlv\HWldHnvckBw\iCSUELBJINifGGueYTpZ{B{fWK3bnn0JIFkfGm4aYT5JIlvKHKjdDDQR|EzKGOnbHzzJIF{e2W|c3XkJIF{KHCqb4PwbIF1\SCuZY\lcEBifCB3IIXNJI1m[XO3cnXkJFMxKHSxIEGyNEBucW6|Lh?= NF3QXY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC1NFE3PSd-MkWwOVAyPjV:L3G+
mouse MN9D cells M3HROWZ2dmO2aX;uJIF{e2G7 NEG4VXMxNjF4IN88US=> NVHSRmFkOjRiaB?= MW\O[ZVzd3C{b4TlZ5RqfmViYXP0bZZqfHliaX6gcY92e2ViTV65SEBk\WyuczDhd5Nme3OnZDDhd{B{fGmvdXzheIlwdiCxZjDCSG5HKGW6cILld5Nqd25iYYSgNE4yPiC3TTDh[pRmeiB{NDDodpM> NWH3NGFJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOVAyPjVpPkK1NFUxOTZ3PD;hQi=>
mouse MN9D cells NEL0TFRHfW6ldHnvckBie3OjeR?= MV2wMlE3KM7:TR?= MYq3NkBp NWGzcXJNVmW3cn;wdo91\WO2aY\lJIFkfGm4aYT5JIlvKG2xdYPlJG1PQURiY3XscJMh[XO|ZYPz[YQh[XNiYnzvZ4tqdmdib3[gWG5HNWGucHjhJIF{e2:laXH0[YQhfG:6aXPpeJkh[XRiMD6xOkB2VSCjZoTldkA4OiCqcoOgZpkhXHK7cHHuJIJtfWVic4ThbY5qdmdw MnXmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUCxOlUoRjJ3MEWwNVY2RC:jPh?=
CHO MXzGeY5kfGmxbjDhd5NigQ>? NGHtU4tFcXOybHHj[Y1mdnRib3[gX|M{WF2|cHjpcodwe2mwZTCxJJBpd3OyaHH0[UBnem:vIHj1cYFvKFNzUEGgdoVk\XC2b4Kg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyxiSVO1NF0xNjh2zszNMi=> NGLhRoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNU[xOVUyOyd-MUW2NVU2OTN:L3G+
CHO NGPzT|VHfW6ldHnvckBie3OjeR?= MXfEbZNxdGGlZX3lcpQhd2ZiW{OzVH1{eGirbnfvd4lv\SBzIIDoc5NxcGG2ZTDmdo9uKGi3bXHuJHMyWDVicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGNJVyClZXzsd{whUUN3ME2yMlHPxE1w M3GwPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkG1OVE{Lz5zNU[xOVUyOzxxYU6=
Jurkat MmfFSpVv[3Srb36gZZN{[Xl? NVzFUINKOThiaILz M4e5UnJmfmW{c3HsJI9nKGmwaHnibZRqd25ib3[gcYl1d2Oqb37kdolidCCodX7jeIlwdiCrbjDoeY1idiCMdYLrZZQh[2WubIOgZYZ1\XJiMUigbJJ{KGmwIIDy[ZNmdmOnIH;mJHouXkGGLX\tby=> M3PJTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NECwOVU2Lz5zN{SwNFU2PTxxYU6=
T-cells MUnGeY5kfGmxbjDhd5NigQ>? MlW5PVYhcHK| M2Dq[WludXWwb4P1dJBz\XO|aY\lJIFkfGm4aYT5JIlvKEKDTFKvZ{9EPTeETD:2JI1wfXOnIGSgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCjbHzvZY51cWenbj3pcoR2[2WmIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB7NjDodpMh[nlibXXhd5VzcW6pIGuzTH11cHmvaXTpcoUhfXC2YXvlJIJ6KG2reHXkJIx6dXCqb3P5eIUhemWjY4Tpc44h[XO|YYmsJGlEPTB;MD6wNFYy|ryPLh?= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR3NkWyOEc,OjF2NU[1NlQ9N2F-
SK-BR-3 MWPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MV[3PEBpenN? MUHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONLVLSMVMh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO|ghcHK|IHL5JHdUXC1zIHHzd4F6NCCLQ{WwQVXPxE1w NETzXVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS1OlUzPCd-MkG0OVY2OjR:L3G+
MDA-MB-231 Mlv3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M1jmNFc5KGi{cx?= M4PjXGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ|MTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5ODDodpMh[nliV2PUMVEh[XO|YYmsJGlEPTB;Nd88UU4> MlG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NU[1NlQoRjJzNEW2OVI1RC:jPh?=
HCT116 M2Lk[WFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MYi3PEBpenN? MlyzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO|ghcHK|IHL5JHdUXC1zIHHzd4F6NCCLQ{WwQVXPxE1w MnHvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NU[1NlQoRjJzNEW2OVI1RC:jPh?=
SW620 MlThRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M2jVNlc5KGi{cx?= MonoRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVV{[yNEBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3PEBpenNiYomgW3NVNTFiYYPzZZktKEmFNUC9Oe69VS5? Ml7tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NU[1NlQoRjJzNEW2OVI1RC:jPh?=
MCF7 NECwSZVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NIDGTpQ4QCCqcoO= MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{igbJJ{KGK7IGfTWE0yKGG|c3H5MEBKSzVyPUZOwG0v NUfkNVVRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OVY2OjRpPkKxOFU3PTJ2PD;hQi=>
LNCAP-AI NF\KVWVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MYe3PEBpenN? NVXyZYx2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcHWvYX6gUG5ESVBvQVmgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{igbJJ{KGK7IGfTWE0yKGG|c3H5MEBKSzVyPUZOwG0v MofTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NU[1NlQoRjJzNEW2OVI1RC:jPh?=
MGC803 NFXZ[pFCdnSrdIXtc5Ih[XO|YYm= M3X0[FExKG2pL3vn M{TUSFIxKGSjeYO= NWDtW|VxSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUWdEQDB|IHPlcIx{KHinbn;ndoFnfGWmIHnuJI52\GVibX;1d4Uh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB1fW2xcjDndo94fGhiYYSgNVAhdWdxa3eg[o9zKDJyIHThfZM> MljuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NU[1NlQoRjJzNEW2OVI1RC:jPh?=
U2OS NVjGPWlrTnWwY4Tpc44h[XO|YYm= MWixPEBpenN? NGG3dndC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHMyWDFicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGVFTzFvYnzhJHUzV1NiY3XscJMhcW6ldXLheIVlKG[xcjCxPEBpenNicILpc5IhfG9iR3XuRoxigmW{IIP1ZpN1emG2ZTDh[IRqfGmxbjDifUBj\XSjLXHydoV{fGmwIILlZ5J2cXSvZX70JIF{e2G7LDDFR|UxRTBwMEC3Nu69VS5? MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ6N{S4O{c,OjZ4OEe0PFc9N2F-
FL5.12A MX;DfZRwfG:6aXPpeJkh[XO|YYm= NHXD[WQ1QCCqcoO= M1TsUWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGZNPS5zMlGgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KESDUFmgd5RicW6rbnetZoF{\WRiZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVIvPM7:TT6= NFjJe2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{S3OVU{PCd-Mke0O|U2OzR:L3G+
SH-SY5Y MmTRR5l1d3SxeHnjbZR6KGG|c3H5 NWC3VXZEOjRiaILz NXPUNHkxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0hvU2m1XUBk\WyuczDt[YF{fXKnZDDh[pRmeiB{NDDodpMh[nliY4L5d5RidC24aX;s[ZQhe3SjaX7pcoch[mG|ZXSgZZN{[XluIFXDNVA:OC53NN88UU4> M{jTNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGzNVE2Lz5{N{mxN|EyPTxxYU6=
SK-N-SH NXO1WFMyS3m2b4TvfIlkcXS7IHHzd4F6 MX6yOEBpenN? M1z4[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMNU5vU1igZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhOjRiaILzJIJ6KGO{eYP0ZYwufmmxbHX0JJN1[WmwaX7nJIJie2WmIHHzd4F6NCCHQ{GwQVAvPTYQvF2u M1nDXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGzNVE2Lz5{N{mxN|EyPTxxYU6=
U118MG MVPDfZRwfG:6aXPpeJkh[XO|YYm= M2q4[|I1KGi{cx?= NInZT4tEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWOTF6TVegZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhOjRiaILzJIJ6KGO{eYP0ZYwufmmxbHX0JJN1[WmwaX7nJIJie2WmIHHzd4F6NCCHQ{GwQVAvPjIQvF2u NXPmcmNnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5NVMyOTVpPkK3PVE{OTF3PD;hQi=>
SH-SY5Y NEnvfm1HfW6ldHnvckBie3OjeR?= M2\DVWFod26rc4SgZYN1cX[rdImgZZQhe3CqaX7nc5NqdmVvMT3wbI9{eGijdHWgdoVk\XC2b4KgbY4hcHWvYX6gV2guW1l3WTDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBkSU2SIHzleoVtKGG2IFXDNVAh[nliZHny[YN1KGmvbYXuc4F{e2G7 NG\4fmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxN|EyPSd-Mke5NVMyOTV:L3G+
U118MG MUnGeY5kfGmxbjDhd5NigQ>? MUnB[49vcXO2IHHjeIl3cXS7IHH0JJNxcGmwZ3;zbY5mNTFvcHjvd5Bp[XSnIILlZ4VxfG:{IHnuJIh2dWGwIGWxNVhOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDjRW1RKGyndnXsJIF1KEWFMUCgZpkh\Gm{ZXP0JIludXWwb3Hzd4F6 NHfqOoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxN|EyPSd-Mke5NVMyOTV:L3G+
SK-N-SH MWTGeY5kfGmxbjDhd5NigQ>? MlPhRYdwdmm|dDDhZ5Rqfmm2eTDheEB{eGirbnfvd4lv\S1zLYDoc5NxcGG2ZTDy[YNmeHSxcjDoeY1idiCVSz3OMXNJKGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHPBUXAhdGW4ZXygZZQhTUNzMDDifUBlcXKnY4SgbY1ufW6xYYPzZZk> MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzlzM{GxOUc,Ojd7MUOxNVU9N2F-
HEK293 NG\j[mJHfW6ldHnvckBie3OjeR?= NYfr[W46OThiaILz MlHoRYdwdmm|dDDhZ5Rqfmm2eTDheEB{eGirbnfvd4lv\S1zLYDoc5NxcGG2ZTDy[YNmeHSxcjCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4h[0GPUDDs[ZZmdCCjdDDFR|ExKGGodHXyJFE5KGi{czDifUBEWkVvcnXzdI9ve2m4ZTDy[Y5qdGyjIHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfS=> NGmwUZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxN|EyPSd-Mke5NVMyOTV:L3G+
SJ-GBM2 MnXqdWhVWyCjc4PhfS=> MVXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= NXrsTHBMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 MUXxTHRUKGG|c3H5 NFXnW3lyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= NGrpeoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC NXPYc49yeUiWUzDhd5NigQ>? NVnWN2ExeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-37 NX76NWF4eUiWUzDhd5NigQ>? NVSx[|A1eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz M3jaXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 NEnrOnVyUFSVIHHzd4F6 NXvHWFN7eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM> NWDKXWdFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2 M1fufJFJXFNiYYPzZZk> MmXYdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?= M{PuSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH M2jyfZFJXFNiYYPzZZk> NFPaO4pyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=> MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB1643 NVvmUYZTeUiWUzDhd5NigQ>? NYjrbpk{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=> M1PNV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5 NGr0RZhyUFSVIHHzd4F6 M4nCUpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?= MlzKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-12 M3jrUZFJXFNiYYPzZZk> Mn7vdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy| M2rHbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18 M3H0S5FJXFNiYYPzZZk> MXrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>? M{\HPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50 Mlj4dWhVWyCjc4PhfS=> Mmf1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD NXPrbpN7eUiWUzDhd5NigQ>? MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM> MnToQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R) NXLIfW5qeUiWUzDhd5NigQ>? MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN? MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh30 M4TTe5FJXFNiYYPzZZk> NWH5RXNbeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoN|Ah[2WubIO= NXXNcWw{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41 NHnQTm5yUFSVIHHzd4F6 NV3COIxYeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO= MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
FL5.12 NWTpcmJSS3m2b4TvfIlkcXS7IHHzd4F6 MUO0PEBpenN? NYnQfXZmS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhTkx3LkGyJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCGQWDJJI9zKHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG|ZXSg[oxwfyCleYTvcYV1emmlIHHuZYx6e2m|LDDJR|UxRTJwMd88UU4> MlfDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{OUK4PVgoRjNyMkmyPFk5RC:jPh?=
FL5.12 NWLYN5F[S3m2b4TvfIlkcXS7IHHzd4F6 MXOxNEB2VQ>? M1XUTFMhcHK| NEPiOVdEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBHVDVwMUKgZ4VtdHNiYYPz[ZN{\WRiYYOgeoFkfW:uZTDmc5Ju[XSrb36gZZQhOTBidV2gZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJI1q[3Kxc3PvdIlkKGGwYXz5d4l{ MmDtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{OUK4PVgoRjNyMkmyPFk5RC:jPh?=
FL5.12 MXXDfZRwfG:6aXPpeJkh[XO|YYm= NUPwO5pKOi53IIXN M3vVe|MhcHK| NF;IUIpEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBHVDVwMUKgZ4VtdHNiYYPz[ZN{\WRiYYOgeoFkfW:uZTDmc5Ju[XSrb36gZZQhOi53IIXNJIFnfGW{IEOgbJJ{KGK7IH\seY9z\XOlZX7j[UBucWO{b4Pjc5Bq[yCjbnHsfZNqew>? NWTXeZI5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyPVI5QThpPkOwNlkzQDl6PD;hQi=>
HepG2 Ml61dWhVWyCjc4PhfS=> NUHnSpZXUGWyR{KgZ4VtdHNidnnhZoltcXS7IIHIWHMh\m:{IGrpb4Ehfmm{dYOgbY5pcWKrdH;ydy=> M4TEW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzN|MkK5OVQ2Lz5|M{KyPVU1PTxxYU6=
CHO M3nY[WZ2dmO2aX;uJIF{e2G7 MofIRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDTNXA{KHKnY3XweI9zKGW6cILld5Nm\CCrbjDDTG8h[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iY3HsZ4l2dSCobIX4JIJ6KGGncYXvdolvNWSncnn2[YQhdHWvaX7ld4NmdmOnIHHzd4F6NCCHQ{WwQVIvPTFzOEpOwG0v Mo\HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|E1QDV2Lze+R4hGVUKOPD;hQi=>
CHO M3LESWZ2dmO2aX;uJIF{e2G7 Mo\PRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDTNXA2KHKnY3XweI9zKGW6cILld5Nm\CCrbjDDTG8h[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iY3HsZ4l2dSCobIX4JIJ6KGGncYXvdolvNWSncnn2[YQhdHWvaX7ld4NmdmOnIHHzd4F6NCCHQ{WwQVMvOTZ{MklOwG0v M4X3elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMyPDh3ND:nQmNpTU2ETEyvZV4>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p-mTOR / mTOR / p-GSK3β / GSK3β / p-IKKα/β / IKKα / NF-κB / Survivin; 

PubMed: 28717222     


Dose-dependent effects of FTY720 on the phosphorylation of Akt, mTOR, GSK3β, and IKKα/β, and the expression of NF-κB, and survivin in SCC2095 cells. Cells were treated with FTY720 in 5% FBS-supplemented DMEM/F12 medium for 24h, and cell lysates were immunoblotted as described in Material and Methods

p-STAT3 / STAT3 / Bcl-xl / Bcl-2 / Bax ; 

PubMed: 25344679     


CC cells were treated for 24 h with or without FTY720 and analyzed for the indicated protein by western blotting. 

Cyclin D1 / CDK4 / cyclin E / CDK2 / p27 / p16 ; 

PubMed: 25344679     


FTY720 induces expression of p16 and p27 and reduces expression of cyclin D1, CDK4, cyclin E and CDK2. CC cells were treated with FTY720 at the indicated concentrations for 24 h. Lysates were then prepared immediately and analyzed by western blotting for cyclin D1, CDK4, cyclin E, CDK2, p16 and p27. β-Actin was used as the internal control. All assays were done in triplicate. 

28717222 25344679
Immunofluorescence
NF-κB; 

PubMed: 28717222     


Effect of FTY720 on the nuclear translocation of NF-κB. SCC2095 cells were treated with 5μM FTY720 for 24h, stained with anti-NF-κB, and examined by confocal microscopy.

N-cadherin / Vimentin ; 

PubMed: 25344679     


Single and merged images show immunofluorescence staining of N-cadherin (green) and vimentin (red). The cell nucleus is stained blue by DAPI.

28717222 25344679
Growth inhibition assay
Cell viability; 

PubMed: 28717222     


Effect of FTY720 at the indicated concentrations on the viability of oral cancer cells. Cells were treated with FTY720 in 5% FBS-supplemented DMEM/F12 medium in 96- well plates at 24h, and cell viability was assessed by MTT assays. Points, means; bars, S.D. (n=6). *P<0.01 compared to the control group.

28717222
In vivo FTY720 is effective in Ph+ but not Ph- ALL xenografts using an early disease model. FTY720 produces a significant reduction in disease burden in the Ph+ ALL xenografts using an early disease model. Ph+ human ALL xenografts responds to FTY720 with an 80 % reduction in overall disease if treatment has been initiated early on. In contrast, treatment of mice with FTY720 does not result in reduced leukemia compared to controls using four separate human Ph- ALL xenografts. [3]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: Immature DCs
  • Concentrations: 10 nM
  • Incubation Time: 4 hours
  • Method: Immature DCs are left intact or are incubated with 2 μM S1P, 10 nM FTY720, 10 nM SEW2871 or the combinations of S1P with these drugs for 4 hours. As a control 1 μg/mL LPS is used. The cells are washed and incubated in a 96-well plate (v-bottom, 2 × 105 cells per well), washed again and resuspended in PBS buffer containing 0.1% sodium azide. They are labeled with 1 μg/mL FITC-conjugated mouse anti-human CD80, 1 μg/mL FITC-conjugated mouse anti-human CD83, 1 μg/mL FITC-conjugated mouse anti-human CD86, 1 μg/mL FITC-conjugated mouse anti-human HLA-class I, 1 μg/mL FITC-conjugated mouse anti-human HLA-DR, 1 μg/mL FITC-conjugated mouse anti-human HLA-E, or 1 μg/mL FITC-conjugated mouse IgG as a control. The cells are washed twice, and examined in the flow cytometer. Markers are set according to the isotype control FITC-conjugated mouse IgG. To stain NK cells with antibodies for various NK cell activating receptors, they are either left untreated or incubated with 2 μM S1P for 4 hours, washed and stained with 1 μg/mL PE-conjugated mouse anti-human NKp30 (CD337), 1 μg/mL PE-conjugated mouse anti-human NKp44 (CD336), 1 μg/mL PE-conjugated mouse anti-human NKG2D (CD314), or as a control 1 μg/mL PE-conjugated mouse IgG1, for 45 min at 4 °C. NK cells are also stained with 1 μg/mL FITC-conjugated anti-killer inhibitory receptor (KIR)/CD158 antibody which recognizes KIR2DL2, KIR2DL3, KIR2DS2 and KIR2DS4, and as a control with FITC-conjugated mouse IgG. The cells are washed twice, and examined in the flow cytometer. Markers are set according to the isotype control PE-conjugated or FITC-conjugated mouse IgG.
    (Only for Reference)
Animal Research:[3]
- Collapse
  • Animal Models: NOD/SCIDγc−/− mice bearing ALL cells.
  • Dosages: 5 mg/kg/day, 10 mg/kg/day
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (200.63 mM)
Water 69 mg/mL (200.63 mM)
Ethanol ''69 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 343.9
Formula

C19H33NO2.HCl

CAS No. 162359-56-0
Storage powder
in solvent
Synonyms N/A
Smiles CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

S1P Receptor Signaling Pathway Map

Related S1P Receptor Products

Tags: buy Fingolimod (FTY720) HCl | Fingolimod (FTY720) HCl supplier | purchase Fingolimod (FTY720) HCl | Fingolimod (FTY720) HCl cost | Fingolimod (FTY720) HCl manufacturer | order Fingolimod (FTY720) HCl | Fingolimod (FTY720) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID